source
- Novartis' experimental drug fails pivotal trial for rare neuromuscular diseaseNovartis reported that its experimental therapy for a rare neuromuscular disorder did not improve muscle function in a pivotal study, missing its primary endpoints. The failure represents the comp…
- FDA approves AstraZeneca's oral SERD Etcamah for HR+/HER2-negative advanced breast cancerFDA granted approval to AstraZeneca's camizestrant, marketed as Etcamah, an oral selective estrogen receptor degrader (SERD) for a specific subset of advanced breast cancer patients. The indicatio…